INDEX TO VOLUME 166

Author Index

Aarden, L., 453
Aarnaes, S., 421
Aasen, S., 812
Abdel-Wahab, M. F., 265
Ablashi, D. V., 690
Abrams, E., 892
Abrams, M. E., 1401
Accordini, A., 1408
Acevedo, R., 1276
Achtman, M., 1316
Adams, R. J., 738
Addiss, D., 673
Agata, N. N., 359
Aggarwal, P., 215
Agis, F., 212
Agoki, E., 86, 919
Agosti, J. M., 244
Agostini, C., 731
Ahmed, F., 1029, 1251
AIDS Vaccine Clinical Trials Network, 244
Albrecht, M. A., 494
Albrecht, P., 205
Aldous, M. B., 646
Aleotti, A., 689
Alexander, L. K., 978
Alexander, S. S., 896
Alim, A. R. M. A., 792
Alimenti, A., 1146
Allen, I. A., 1367
Allphin, A. A., 1346
Allworth, A. M., 939
Alpers, M. P., 1453
Alter, M. J., 518
Altman, R., 896
Alugupalli, S., 1177
Alvarado, F., 139
Amador, R., 139
Anderson, B. C., 531
Anderson, D. C., 818
Anderson, M., 738
Anderson, R., 568
Andersson, T., 854
Antoni, M., 449
Araki, S., 943
Armstrong, D., 686
Armstrong, J. A., 717
Arnold, J. E., 1346
Arvin, A. M., S6
Asano, Y., S10
Asher, D. M., 113
Ashkenazi, S., 832
Ashman, R. B., 947
Astemborski, J., 685
Aussage, P., 93
Baba, K., S10
Baca, N. G., 1429
Bacher, J., 121
Bagby, G. J., 336
Bailey, R. L., 1173
Bajpai, V. K., 938
Bakchine, S., 888
Baker, C. J., 1079
Baker-Zander, S. A., 1449
Bakker, M., 620
Baldwin, B., 628
Balish, E., 1194
Balish, M. J., 1401
Bamji, M., 892
Banik, A. R., 1029
Banks, S., 500
Baqui, A. H., 792
Barclay, G. R., 1051
Baric, R. S., 978
Barki, Y., 695
Baron, R., 673
Barra, A., 1021
Barreto, L., 1436
Barry, K., 551
Bartholeyns, J., 93
Bartlett, J. G., 277
Bassily, S., 265
Baudrimont, M., 1416
Bayer, A. S., 65
Bean, N. H., 1429
Bechet, J.-M., 888
Beck, J. S., 182
Beingolea, L., 1429
Belitsos, P. C., 277
Belshe, R. B., 244
Benichou, C., 657
Benoliel, A. M., 1097
Bensasi, S., 717
Bergeret, M., 657
Bergholm, A.-M., 31
Berman, J. W., 598
Bermudez, L. E., 923
Bernard, G. R., 134
Berneman, Z. N., 690
Bhat, B. M., 769
Bhat, R. A., 769
Biggar, R. J., 100
Birch, C. J., 108
Birch, C., 1139
Bistoni, F., 1384
Biswas, R., 424
Black, R. E., 792
Blake, M. S., 551, 1316
Blanchard, D. K., 1089
Blanding, J., 421
Blanes, N., 611
Blaser, M. J., 1073
Blattner, W. A., 100
Blumberg, H. M., 574
Bongrand, P., 1097
Bonnotte, B., 428
Booth, J. L., 1188
Borkowsky, W., 616
Bornstein, N., 22
Borrebaeck, C. A. K., 1322
Boslego, J., 158
Bothamley, G. H., 182
Bouffard, P., 1276
Bouldin, T. W., 80
Boulos, R., 194, 418
Bourliere, M., 449
Bovenzi, P., 689
Bowler, W. A., 885
Boxerbaum, B., 1006, 1346
Boyle, M. D. P., 436
Brammer, T. L., 753
Brandt, C. R., 1401
Brandtzaeg, P., 650
Brauer, J. E., 500
Brawner, D. L., 587
Brechot, C., 1192
Breiman, R. F., 1346
Britigan, B. E., 1375
Brodie, S. J., 531
Brodine, S. K., 885, 1149
Broeders, P. H. M., 169
Brons, N. H. C., 1228
Brooks, G. F., 1316
Broome, C. V., 359
Brouqui, P., 660
Brown, A. E., 145, 1465
Brown, B. A., 405
Brown, B. G., 753
Brown, D. R., 512
Brown, S. T., 686
Browne, M., 480
Bruderer, U., 344
Bruisten, S. M., 620
Brundage, J. F., 365
Brunell, P. A., S7
Brus, I., 690
Bruyn, G. A. W., 1460
Bryan, C. S., 556
Bryan, J. T., 512
Bryant, A. E., 165
Bryant, R. G., 1281
Brytting, M., 1408
Buchbinder, S. P., 1153
Buckle, G. J., 113
Buckner, C., 1160
Burgos, C., 885
Burke, J. F., 556
Burnie, J., 1193
Burns, S. M., 704
Caburet, F., 1416
Cacopardo, B., 448
Caenazzo, C., 731
Caillot, D., 428
Calderon, T. M., 598
Callahan, M. V., 1204
Callender, D., 121
Calvo, J. C., 139
Campbell, C. C., 1458
Campos, J., 173
Cannon, R. O., 892
Cantorna, M. T., 1194
Canu, A., 958
Cao, P., 1073
Cao, S.-N., 525
Cao, W., 446
Caprioli, A., 154
Carbonaro, C. A., 1462
Carpenter, C. C. J., 2
Carper, H. T., 664
Carreño, V., 1200
Cartouzou, G., 449
Casasnovas, O., 428
Caselmann, W. H., 966
Cassai, E., 689
Cassone, A., 1103
Castagna, A., 1408
Castro, J., 139
Causey, D. M., 607
Celentano, D. D., 685
Celesia, B. M., 448
Cenci, E., 1384
Cermelli, C., 689
Cerny, A., 285
Chaisson, R. E., 194, 1223
Chakraborty, J., 1029
Chamberlin, C. J., 885
Chamot, E., 269
Chan, L., 1160
Chang, A. H., 911
Chanock, R. M., 769
Chao, C. C., 847
Charuzi, I., 695
Chavanet, P., 428
Cheang, M., 86
Chen, D.-S., 900, 1167
Chen, M., 149
Chen, P.-J., 900
Chen, S., 1199
Chheang, C., 413
Chia, J. K. S., 1196
Chmiel, J. S., 1217
Choi, C. S., 847
Chongsuphajaisiddhi, T., 1393
Chotard, J., 764
Chou, S., 604
Chou, T.-C., 1143
Chou, W.-H., 1425
Chow, A. W., 911
Chowdhury, H. R., 792
Christopher, N. C., 1079
Christy, C., 235
Chulay, J. D., 1184
Ciardi, M., 350
Cieplak, W., Jr., 308

INDEX TO VOLUME 166

Author Index

Aarden, L., 453
Aarnaes, S., 421
Aasen, S., 812
Abdel-Wahab, M. F., 265
Ablashi, D. V., 690
Abrams, E., 892
Abrams, M. E., 1401
Accordini, A., 1408
Acevedo, R., 1276
Achtman, M., 1316
Adams, R. J., 738
Addiss, D., 673
Agata, N. N., 359
Aggarwal, P., 215
Agis, F., 212
Agoki, E., 86, 919
Agosti, J. M., 244
Agostini, C., 731
Ahmed, F., 1029, 1251
AIDS Vaccine Clinical Trials Network, 244
Albrecht, M. A., 494
Albrecht, P., 205
Aldous, M. B., 646
Aleotti, A., 689
Alexander, L. K., 978
Alexander, S. S., 896
Alim, A. R. M. A., 792
Alimenti, A., 1146
Allen, I. A., 1367
Allphin, A. A., 1346
Allworth, A. M., 939
Alpers, M. P., 1453
Alter, M. J., 518
Altman, R., 896
Alugupalli, S., 1177
Alvarado, F., 139
Amador, R., 139
Anderson, B. C., 531
Anderson, D. C., 818
Anderson, M., 738
Anderson, R., 568
Andersson, T., 854
Antoni, M., 449
Araki, S., 943
Armstrong, D., 686
Armstrong, J. A., 717
Arnold, J. E., 1346
Arvin, A. M., S6
Asano, Y., S10
Asher, D. M., 113
Ashkenazi, S., 832
Ashman, R. B., 947
Astemborski, J., 685
Aussage, P., 93
Baba, K., S10
Baca, N. G., 1429
Bacher, J., 121
Bagby, G. J., 336
Bailey, R. L., 1173
Bajpai, V. K., 938
Bakchine, S., 888
Baker, C. J., 1079
Baker-Zander, S. A., 1449
Bakker, M., 620
Baldwin, B., 628
Balish, E., 1194
Balish, M. J., 1401
Bamji, M., 892
Banik, A. R., 1029
Banks, S., 500
Baqui, A. H., 792
Barclay, G. R., 1051
Baric, R. S., 978
Barki, Y., 695
Baron, R., 673
Barra, A., 1021
Barreto, L., 1436
Barry, K., 551
Bartholeyns, J., 93
Bartlett, J. G., 277
Bassily, S., 265
Baudrimont, M., 1416
Bayer, A. S., 65
Bean, N. H., 1429
Bechet, J.-M., 888
Beck, J. S., 182
Beingolea, L., 1429
Belitsos, P. C., 277
Belshe, R. B., 244
Benichou, C., 657
Benoliel, A. M., 1097
Bensasi, S., 717
Bergeret, M., 657
Bergholm, A.-M., 31
Berman, J. W., 598
Bermudez, L. E., 923
Bernard, G. R., 134
Berneman, Z. N., 690
Bhat, B. M., 769
Bhat, R. A., 769
Biggar, R. J., 100
Birch, C. J., 108
Birch, C., 1139
Bistoni, F., 1384
Biswas, R., 424
Black, R. E., 792
Blake, M. S., 551, 1316
Blanchard, D. K., 1089
Blanding, J., 421
Blanes, N., 611
Blaser, M. J., 1073
Blattner, W. A., 100
Blumberg, H. M., 574
Bongrand, P., 1097
Bonnotte, B., 428
Booth, J. L., 1188
Borkowsky, W., 616
Bornstein, N., 22
Borrebaeck, C. A. K., 1322
Boslego, J., 158
Bothamley, G. H., 182
Bouffard, P., 1276
Bouldin, T. W., 80
Boulos, R., 194, 418
Bourliere, M., 449
Bovenzi, P., 689
Bowler, W. A., 885
Boxerbaum, B., 1006, 1346
Boyle, M. D. P., 436
Brammer, T. L., 753
Brandt, C. R., 1401
Brandtzaeg, P., 650
Brauer, J. E., 500
Brawner, D. L., 587
Brechot, C., 1192
Breiman, R. F., 1346
Britigan, B. E., 1375
Brodie, S. J., 531
Brodine, S. K., 885, 1149
Broeders, P. H. M., 169
Brons, N. H. C., 1228
Brooks, G. F., 1316
Broome, C. V., 359
Brouqui, P., 660
Brown, A. E., 145, 1465
Brown, B. A., 405
Brown, B. G., 753
Brown, D. R., 512
Brown, S. T., 686
Browne, M., 480
Bruderer, U., 344
Bruisten, S. M., 620
Brundage, J. F., 365
Brunell, P. A., S7
Brus, I., 690
Bruyn, G. A. W., 1460
Bryan, C. S., 556
Bryan, J. T., 512
Bryant, A. E., 165
Bryant, R. G., 1281
Brytting, M., 1408
Buchbinder, S. P., 1153
Buckle, G. J., 113
Buckner, C., 1160
Burgos, C., 885
Burke, J. F., 556
Burnie, J., 1193
Burns, S. M., 704
Caburet, F., 1416
Cacopardo, B., 448
Caenazzo, C., 731
Caillot, D., 428
Calderon, T. M., 598
Callahan, M. V., 1204
Callender, D., 121
Calvo, J. C., 139
Campbell, C. C., 1458
Campos, J., 173
Cannon, R. O., 892
Cantorna, M. T., 1194
Canu, A., 958
Cao, P., 1073
Cao, S.-N., 525
Cao, W., 446
Caprioli, A., 154
Carbonaro, C. A., 1462
Carpenter, C. C. J., 2
Carper, H. T., 664
Carreño, V., 1200
Cartouzou, G., 449
Casasnovas, O., 428
Caselmann, W. H., 966
Cassai, E., 689
Cassone, A., 1103
Castagna, A., 1408
Castro, J., 139
Causey, D. M., 607
Celentano, D. D., 685
Celesia, B. M., 448
Cenci, E., 1384
Cermelli, C., 689
Cerny, A., 285
Chaisson, R. E., 194, 1223
Chakraborty, J., 1029
Chamberlin, C. J., 885
Chamot, E., 269
Chan, L., 1160
Chang, A. H., 911
Chanock, R. M., 769
Chao, C. C., 847
Charuzi, I., 695
Chavanet, P., 428
Cheang, M., 86
Chen, D.-S., 900, 1167
Chen, M., 149
Chen, P.-J., 900
Chen, S., 1199
Chheang, C., 413
Chia, J. K. S., 1196
Chmiel, J. S., 1217
Choi, C. S., 847
Chongsuphajaisiddhi, T., 1393
Chotard, J., 764
Chou, S., 604
Chou, T.-C., 1143
Chou, W.-H., 1425
Chow, A. W., 911
Chowdhury, H. R., 792
Christopher, N. C., 1079
Christy, C., 235
Chulay, J. D., 1184
Ciardi, M., 350
Cieplak, W., Jr., 308

Cinque, P., 1408
Cipriani, A., 731
Cirrincione, R., 154
Clabots, C. R., 561
Claesson, B. A., 1335
Clarke, I. N., 1173
Clauvel, J. P., 1462
Cleary, T. G., 832
Clemens, J. D., 1029, 1251
Clements, J. E., 738
Clements, M. L., 244
Clerici, M., 723
Clermont, H. C., 194
Close, K., 847
Coberly, J. S., 194
Cohen, J., 331
Cohen, J. B., 74
Cohen, M. S., 1375
Cohrs, R., S4, S5
Cole, P. J., 568
Collins, P. L., 769
Conly, J., 1197
Connelly, B. L., S8
Constantine, N. T., 265
Cooperstock, M., 682
Cordonnier, C., 1021
Corey, L., 1, 244
Coronell, C., 139
Cosentino, S., 448
Coster, J. M., 209
Cosyns, M., 260
Cote, P. J., 628
Cotte, L., 447
Coutellier, A., 611
Coutinho, R. A., 620
Cover, T. L., 1073
Cox, J. H., 972
Cregan, P., 191
Critchlow, C., 1362
Cruz, S., 1322
Cryz, S. J., Jr., 344, 451
Cryz, S. J., 837
Dale, P. A., 316
Daley, G., 1403
D'Allesandro, U., 842
Dankert, J., 1340
Darnell, M. E. R., 1422
da Silva Cardoso, M., 450
Dauber, J. H., 926
Daugelat, S., 186
Daum, R. S., 1066
Davis, A. R., 769
Davis, H. L., 194
Davis, R. B., 607
Dawson, C. R., 383
Day, K., 1453
Dazin, P. F., 65
D'Costa, L., 86
D'Costa, L. J., 919
Dean, D., 383
de Boissieu, D., 657
de Gier, H. H. W., 209
de Goede, R. E. Y., 620
Dekker, J. T., 620
de Kossodo, S., 285
de la Concha-Bermejillo, A., 531
de la Maza, L., 421
de Leij, L. H. F. M., 1228
Dellinger, E. P., 556
DeLuca, N., 494
del Valle, J., 1322
Demarquest, J., 611
DeMartini, J. C., 531
Demmrich, Y., 202
Denny, T. N., 896
Deplano, A., 22
Derish, P. A., 74
DesJardin, L. E., 436
Deusinger, M., 344
Devlin, M. E., S5
DeWitt, W., 359
de Wolf, F., 620
Diaz-Mitoma, F., 986
Di Bisceglie, A. M., 424
Dietrich, M., 930
Di Francesco, C., 731
Diglisic, G., 113
Di Luca, D., 689
Dimkovic, N., 113
Dinarello, C. A., 1204
di Padova, F., 1051
Dirks-Go, S., 209
Dirnagl, U., 1442
Djeu, J. Y., 1089, 1103
Dobrescu, C., 336
Doherty, R., 108
Dolin, R., 235, 244
Donnenberg, A. D., 738
Dormont, D., 93
Drancourt, M., 660
Du, G. G., 149
Dudley, M. N., 480
Dueland, A. N., S4, S5
Dunkle, L., 480
Dunne, W. M., Jr., 944
Duvivier, C., 1416
Duym, L., 453
Dwyer, D. E., 888
Echeverria, P., 145, 1295
Edelman, R., 837
Edelson, P. J., 178
Edstein, M. D., 1393
Edwards, S., 978
Eiden, J., 507
Einhäupl, K. M., 1442
Ellis, J. A., 531
Ellis-Pegler, R. B., 687
El-Masry, N. A., 265
Elmwood, P., and Westfall Pediatric Groups, 235
El-On, J., 695
El-Zeiny, A., 1453
Enelow, R. I., 664
Englund, J. A., 1436
Epple, S., 450
Eskola, J., 1340
Esmat, G. E., 265
Espejo, F., 139
Estabrook, M. M., 1079
Esterlitz, J. R., 244
Evans, M. E., 803
Evans, T. G., 1124
Facklam, R., 574
Facklam, R. R., 1346
Factor, S. M., 598
Fairley, C. K., 1199
Falcoff, R., 1203
Falla, J. C., 139
Fällman, M., 854
Farber, B. F., 861
Farfán, R., 139
Farrar, B. B., 753
Farrell, D., 205
Farzadegan, H., 1217
Fatuzzo, F., 448
Feinstone, S. M., 424
Fenouillet, E., 611
Fernández-de-Cossío, M. E., 1322
Fernie, B. F., 244
Fiedler, F., 58
Fierer, J., 639
Filice, G. A., 677
Finelli, L., 1433
Fisher-Hoch, S. P., 753
Fleisher, G., 682
Fornasini, M., 326
Forrest, B. D., 210
Forthal, D. N., 421
Fossati, L., 285
Foung, S. K. H., 1160
Fournier, M. A., 546
Foy, H. M., 646
Francavilla, E., 731
Franco, L., 139
Frank, M. M., 1245
Frenkel, N., 690
Friedlander, A. M., 1184
Fritzell, B., 1021
Froebel, K. S., 704
Frost, J. W., 972
Fujikawa, J., 162
Fujita, S., 1205
Fukuda, K., 1192
Fukuda, S., 1157
Fung, J., 1379
Furlini, G., 710
Furukawa, S., 691
Furuta, Y., 1157
Fusté, M. C., 173
Fyhrquist, F., 432
Gaccione, P., 717
Gajdusek, D. C., 113
Gallant, J. E., 1223
Gallati, H., 930
Gallo, R. C., 690
Galloway, D. A., 1209
Gambertoglio, J. G., 473
Garbisa, S., 731
Garland, F. C., 1149
Garland, S., 1199
Garnerin, P., 542
Gedrose, J. K., 518
Geelen-van den Broek, L., 1340
Geletko, S., 480
George, F., 660
George, M. O., 764
Georghiou, P. R., 939
Georgilis, K., 440
Gerding, D. N., 561, 1287
Gerin, J. L., 628
Gerna, G., 1236
Gerolami, V., 449
Gershon, A. A., S11
Gianviti, A., 154
Gibb, A. P., 1051
Gigliotti, F., 1113
Gilden, D. H., S4, S5
Gilmore, M. S., 1188
Glezen, W. P., 1436
Gligic, A., 113
Gluckman, J. C., 611
Goessens, W. H. F., 169
Goforth, R. R., 1149
Goldblatt, D., 632
Golden, M. P., 494
Goldsmith, C. S., 753
Gongora-Biachi, R. A., 1160
Gonzales, J., 951
Gonzalez, P. C., 191
Gordien, E., 212
Gorse, G. J., 244
Gotschlich, E. C., 551
Goudsmit, J., 620
Gozlan, J., 1416
Graham, B. S., 244
Graham, K. K., 480
Graham, S., 704
Grange, J. M., 182
Granowitz, E. V., 1204
Grau, G. E., 58
Gray, G. C., 162
Grayston, J. T., 646
Greene, B. M., 15
Greenson, J. K., 277
Greenwood, A. M., 842
Greenwood, B. M., 842
Grefte, J. M. M., 683
Grieco, M. H., 607
Griffin, D. E., 1170
Griffin, P. M., 1281
Griffiss, J. M., 1079
Grimont, F., 22
Grohmann, U., 1384
Groover, J. E., 38
Grose, C., S2
Grundy, F., 43
Guerra-Romero, L., 546
Guiguet, M., 428
Guiney, D., 639
Gulati, S., 316
Gulle, H., 186
Gumprecht, J. P., 598
Gunzenhauser, J. D., 365
Gupta, P., 717
Gupta, S., 1066

Gupta, U., 215
Guzmán, F., 139
Gwaltney, J. M., Jr., 776
Gyorkos, T. W., 413
Haberl, R. L., 1442
Hadley, W. K., 191
Hadlock, K., 1160
Hahn, B. H., 100
Haidaris, C. G., 1113
Haidaris, P. J., 1113
Haider, K., 792
Halfon, P., 449
Hall, A. J., 764
Hall, C., 80
Hall, F. W., 1149
Halsey, N. A., 194, 418
Hamill, R. J., 38
Hamilton, J. D., 1403
Hammer, C. H., 1245
Hammer, S. M., 494
Han, D. P., 1006
Hanes, M. A., 753
Hara, J., S10
Harboe, M., 874
Hardegen, N. J., 803
Hardie, W. D., 134
Hardy, I., S11
Harris, J. R., 1029
Harrison, L., 418
Hartley, T. M., 892
Hasegawa, A., 227
Hatcher, V. B., 598
Hatheway, C. L., 1281
Hayashi, P. H., 1276
Hayes, K., 108
Hayes, L. J., 1173
Hayes, S. F., 308
Hayward, A., 260
Hayward, A. R., 253
Hazell, S. L., 149
Hazlett, F. E., Jr., 1453
Hedges, S., 653
Heggie, A. D., 1006
Heim, A., 958
Heller, M. V., 1203
Hemmer, C., 930
Hemming, V. G., 1422
Hendrix, C. W., 723
Heneine, W., 892
Henrickson, K. J., 944, 995
Hermann, L. M., 753
Hernandez, S. R., 74
Herrington, D. A., 158
Hertzanu, Y., 695
Hesse, R., 450
Hessel, L., 1021
Hessol, N. A., 1153
Heusser, C., 285
Heyn, A. A., 1228
Heyworth, M. F., 465
Hiemstra, P. S., 1460
Higgins, P. J., 198
Hirozawa, A. M., 74
Hirsch, M. S., 1143
Hirschel, B., 269
Hitt, J. A., 677
Hjelle, B., 1160
Ho, M., 717
Hofschneider, P. H., 958, 966
Hoiseth, S. K., 178
Holbrook, K. F., 556
Holm, S. E., 31, 1014
Holmberg, S. D., 1153
Holmes, K. K., 1362
Holt, E., 418
Hondo, R., 1157
Hooten, T. M., 607
Hoover, W., 616
Hopfer, R. L., 1196
Hopkins, C. C., 556
Hornbuckle, W. E., 628
Horowitz, H., 1462
Hossain, A., 792
Hsu, K.-H. L., 769
Hu, P. J., 149
Hu, S.-L., 244
Hu, S., 847
Hua, T. H., 1311
Huang, X.-L., 717
Hubert, B., 542
Huda, N., 1251
Huggler, E., 58
Hughes, B. J., 818
Huisman, H. G., 620
Hung, P. P., 769
HUS Italian Study Group, 154
Hutwagner, L. C., 753, 1281
Huycke, M. M., 1188
Hyams, K. C., 162
Icenogle, J. P., 1210
Ihara, T., 941
Iketani, T., S10
Ilan, Y., 1164
Ilmet-Moore, T., 616
Inderlied, C. B., 923
Innis, B., 1465
Inoue, Y., 1425
Inouye, S., 227
Inskip, H. M., 764
Intrator, L., 1021
Inuyama, Y., 1157
Irish, W., 1379
Isshiki, G., 1192
Ito, S. I., 1149
Ivanyi, J., 182
Izui, S., 285
Jaccard, A., 1462
Jackson, L. A., 445
Jacobs, F., 22
Jacobs, M. R., 1006, 1346
Jacobson, M. A., 607
Jacomet, C., 1416
Jaffe, E. S., 291
Jagannath, S., 500
Jahan, N., 291
Jahn, G., 683
Jalanko, H., 432
Janoff, E. N., 1287
Janssen, R. A. J., 1228
Jastremski, M., 1367
Jett, B. D., 1188
Jochem, H., 450
Johns Hopkins University/Centre pour le Developpement et la Santé HIV Study Group, 418
Johnson, D. R., 374
Johnson, J. T., 818
Johnson, M. P., 194
Johnson, R. T., 1170
Johnson, S., 561, 1287
Johnson, S. A., 1422
Johnson, V. A., 1143
Jones, H. M., 915
Jordan, M. C., 677
Jovanovic, D., 113
Juaregui, E., 1170
Jurado, R., 1201
Kain, K. C., 145
Kaiser, A. B., 393
Kamiya, H., 941
Kamiya, H., S10
Kandolf, R., 958
Kao, J.-H., 900
Kaper, J. B., 837
Kapikian, A. Z., 235
Kaplan, E. L., 162, 374, 1006
Kaplan, J. E., 892
Kaplan, S. L., 1035
Kapperud, G., 812
Karchmer, A. W., 556
Kardjito, T., 182
Kasper, D. L., 635
Katsafanas, G., 690
Katsuta, T., 1459
Katz, B. P., 512
Katz, M., 695, 1458
Katz, M. H., 1153
Kaufmann, S. H. E., 186
Kaul, A., 616, 892
Kaul, S., 480
Kay, B., 1029
Kazura, J. W., 1453
Keefer, M. C., 244
Kehoe, M. A., 165
Kellie, S., 598
Kelly, D. J., 1184
Kennedy, C. A., 1149
Kennedy, J., 687
Kennedy, S. L., 1045
Kenney, S., 80
Kenya/Centers for Disease Control Meningitis Study Group, 359
Kern, P., 930
Kernodle, D. S., 393
Keruly, J., 1223
Kessler, H. A., 723
Khan, M. R., 1029
Khanna, B. K., 518
Kierulf, P., 650
Kilbourne, B., 892
Kim, S., 494
Kimura-Takeuchi, M., 1266
Kindelan, J. M., 1201
Kinoshita, T., 1459
Kirschner, P., 958
Kisterman, J. P., 428
Kitamura, K., 941
Klein, A., 1164
Klein, C. W., 896
Klempner, M. S., 440
Knowlton, D. R., 1251
Kobayashi, J., 673
Kobayashi, K., 1192
Kobayshi, M., 1459
Ködel, U., 1442
Koerner, K., 450
Koff, W. C., 244
Kohl, S., 623
Kokoskin-Nelson, E., 413
Koles, N. L., 803
Konkel, M. E., 308
Koppelman, M. H. G. M., 620
Korba, B. E., 628
Kornfeld, H., 866
Korvick, J. A., 1198
Koshy, R., 966
Kotwal, G. J., 1245
Koyama, Y., 1295
Kramarsky, B., 690
Krasinski, K., 616, 892
Krause, M., 639
Kremsner, P., 930
Krieger, J. N., 1362
Krishna, S., 1195
Kristiansen, B.-E., 1329
Kronvall, G., 1329
Krueger, J. M., 1266
Kubanek, B., 450
Kunin, C. M., 1311
Kurashige, T., 908
Kuroki, T., 1192
Kusecek, B., 1316
Kusne, S., 1379
Kuusela, P., 1329
Ladd, E. A., 494
Laga, M., 1210
Lagergård, T., 1335
Lai, M.-Y., 900
Lal, R. B., 1160
Lambert, J. S., 244
Lammel, C. J., 1316
Land, S., 1139
Landay, A. L., 723
Landivar, W. H. C., 1464
Lang, A. B., 344
Lang, C. H., 336
Langlois, M., 447
La Placa, M., 710
LaPlace, D., 213
LaRocco, A., 885
La Rosa, R., 448
Larsson, L., 1177
LaRussa, P., S11
Lassen, J., 812
Lassiter, H. A., 53

Latgé, J.-P., 580
Lauwers, S., 22
Lawrence, D. N., 244
Laxer, M. J., 1133
Lazzarin, A., 1192, 1408
Lebon, P., 657
Lederman, H. M., 642
LeDuc, J. W., 113
Lee, A., 149
Lee, D. C., 642
Lee, J. W., 121
Lee, V. T. P., 911
Lefrère, F., 212
Lefrère, J.-J., 212
Leguire, L. E., 525
Lemp, G. F., 74
Le Naour, R., 93
Lesslauer, W., 1045
Lett, S. M., 205
Levin, M., 260
Levin, M. J., 253
Levine, M., 451
Levine, M. M., 158, 837, 1181
Levine, P. H., 291
Levinsky, R. J., 632
Levitz, S. M., 866
Levy, M., 449
Levy, N., 1276
Lew, D. P., 58
Li, Y. Y., 149
Licitra, C., 574
Lidin-Janson, G., 653
Liesnard, C., 22
Lilleby, K., 473
Lima, J. W. de O., 1124
Lin, J.-T., 1167
Lindberg, A. A., 158
Linde, A., 1408
Linz, P. E., 1006
Lipka, J., 1160
Liu, J. Y., 1153
Liu, J. H., 1089
Liu, Q., 149
Llano, M., 1322
Loetscher, H., 1045
Loik, F., 764
Long, C., 235
Looareesuwan, S., 1195
Lopez-Berestein, G., 121
Lorén, J. G., 173
Losikoff, P., 194
Losonsky, G., 451, 837
Lottenberg, R., 436
Lowe, Y., 764
Lubbers, M. J., 1367
Lubeck, M. D., 769
Lucas, C. R., 108
Lucas, R., 1139
Lucey, D. R., 723
Lukehart, S. A., 1449
Lupo, G., 448
Lurain, N. S., 904
Luxemburger, C., 1393
Luzuriaga, K., 1146
Luzzi, I., 154
Lyman, W. D., 699
Lynch, E. A., 1204
Mabey, D. C. W., 1173
Mabondzo, A., 93
Maccario, R., 1236
Mackowiak, P. A., 1181
MacLean, J. D., 413
Madore, H. P., 235
Maes, N., 22
Magder, L., 418
Mahalingam, R., S4, S5
Mahdi, A. A., 938
Mainguene, C., 1462
Maiztegui, J. I., 1203
Majde, J. A., 1266
Mall, G., 958
Maloney, E. M., 100
Manak, M., 291
Mandell, G. L., 664
Mandrell, R. E., 1079
Mañez, R., 1379
Mannix, M. L., 500
Manoka, A. T., 1210
Mao, J., 1375
Marcom, K. A., 531
Margolis, H., 418
Margolis, H. S., 518
Marino, S. K., 556
Mariotti, M., 212
Markowitz, L. E., 205
Marriott, E., 1200
Marsden, H. S., 704
Martin, M., 1379
Martin, T. R., 1354
Martinell, J., 653, 1335
Marullo, S., 1462
Mason, E. O., Jr., 1035
Matheron, S., 888
Matsubara, T., 691
Matsumoto, M., 1295
Matteucci, M. C., 154
Matthews, R., 1193
Maurice, L., 428
Maurin, M., 1097
May, D., 1346
Mayer, K., 480
Mayumi, T., 692
Mazza, P., 710
McAuliffe, I. T., 1124
McCormick, J. B., 753
McCreedy, B. J., 896
McCroskey, L. M., 1281
McDermott, J., 687
McDougal, L. K., 1346
McGavin, C., 1139
McIntyre, M. P., 22
McKenzie, R., 1245
McKinley, G. F., 607
McKinney, K. C., 74
McMahon, D., 717
McNeil, J. G., 365
McQuillen, D. P., 316
Mead, D. J., 308
Mebatsion, T., 972
Meeker, R., 80
Meier, J. L., S3
Melcher, G. P., 121
Mencacci, A., 1384
Mendy, M., 764
Mensah, K., 657
Merino, R., 285
Merrill, D. P., 1143
Mertz, K., 1433
Metsärinne, K., 432
Meyer, M., 966
Meyers, J. D., 473
Meyohas, M.-C., 1416
Michel, M. F., 169
Micic, J., 113
Midthun, K., 244
Mihalik, K., 424
Mijch, A., 108
Mikesell, P., 1184
Milanesi, G., 1236
Milewski, W. M., 1066
Miller, D., 1210
Miller, M. A., 518
Miller, R. N., 365
Milne, A., 942
Miörner, H., 1177
Mirandola, P., 689
Mirza, N. B., 359
Mirzayans, F., 986
Mitchell, H. M., 149
Mitchell, L. A., 1258
Mitcheltree, C., 486
Miyamura, T., 1425
Miyata, N., 943
Mizutani, S., 769
Mochizuki, M., 943
Mok, J. Y. Q., 704
Molano, A., 139
Molinas, F. C., 1203
Molitor, T. W., 847
Moll, B., 1198
Monforte, A. D'A., 1192, 1408
Mongkolsirichaikul, D., 1465
Montagnier, L., 888
Montefiori, D. C., 244
Moore, R. D., 1223
Mora, A. L., 139
Mora, E., 139
Moreno, A., 139
Mori, M., 587
Mori, S., 943
Morrow, A. L., 326
Morse, H. C., III, 285
Mosci, P., 1384
Moscicki, A.-B., 951
Moss, B., 1245
Moss, G., 86
Motohashi, T., 691
Murari, P., 291
Murata, R., 1192
Murdin, A. D., 935
Murillo, L. A., 139
Murphy, B. R., 769
Murphy, W. F., 686
Murray, B. E., 326
Murray, H. W., 686, 938
Murray, M., 253
Musher, D. M., 38
Myers, M. G., S8
Nagasawa, K., 692
Nagashima, K., 1157
Nahmias, A., 418
Nakajima, S., 1192
Nakasa, T., 1464
Nakashima, S., 943
Nakashima, T., 1205
Nakata, M. M., 1196
Nakayama, S., 1295
Narayan, O., 738
Narooz, S., 265
Nassos, P. S., 191
Nataro, J., 837
Navarro, D., 623
Navarro, E., 121
Ndinya-Achola, J. O., 86, 919
Neel, J. V., 100
Neifer, S., 930
Nelson, S., 336
Newburg, D. S., 832
Ng, T. I., S2
Ng, V. L., 191
Ngacha, D. M., 359
Niho, Y., 692
Nilsen, T. W., 1453
Nilsson, E., 854
Nishiguchi, S., 1192
Niu, M. T., 518
Njeru, E., 359
Noel, G. J., 178
Norgren, M., 31, 1014
Norman, D. C., 65
Norrby, A., 31, 1014
Norris, M., 80
Nosten, F., 1393
Notkins, A. L., 500
Novati, R., 1192
Novick, W. J., 847
Nuñez, F., 139
Nunnari, A., 448
NYC Perinatal HIV Transmission Collaborative Study, 892
Obradovic, M., 113
Ochiai, H., 941
Odaka, N., 1217
Ogra, P. L., 936
Ogura, H., 908
Ohkawa, M., 1205
Ohlin, M., 1322
Olanratmanee, T., 451
Oldfield, E. C., III, 885, 1149
Olson, M. M., 561
Olson, P. E., 1149
O'Malley, P. M., 1153
Ombette, J., 86, 919
Onderdonk, A. B., 635
O'Neill, M., 1146
Onyango, F., 359

Onyi, G. O., 405
Orciari, L. A., 296
Orencole, S. F., 1204
Orenstein, W. A., 205
Orozco, M., 139
Ortega, N., 139
Ostroff, S. M., 812
Ottolini, M. G., 1422
Øvstebø, R., 650
Palacios, A. M., 1429
Palefsky, J. M., 951
Palma, C., 1103
Palmblad, J., 854
Palumbo, P. E., 896
Panopoulos, D., 803
Panyim, S., 145
Papdimitriou, J. M., 947
Paradis, I. L., 926
Paradis, T., 198
Parea, M., 1236
Parenti, D. M., 607
Parker, R. A., 393
Partono, F., 453
Pasquini, P., 154
Patarroyo, M. E., 139
Paugh, K., 673
Paveenkittiporn, W., 1295
Paz, K. C., 1464
Paz, P., 623
Pazin, G. J., 717
Peacocke, M., 440
Pearlman, E., 1453
Pearson, L. D., 531
Pearson, R. D., 1124
Peiser, J., 695
Pepin, J., 86
Percivalle, E., 1236
Pereira, L., 623
Perez-Oronoz, G. I., 753
Peri, G., 1236
Perkins, B. A., 359
Perrin, L. H., 269
Peterson, L. R., 561
Peterson, P. K., 847
Petit, J.-C., 1416
Pettinger, M., 1445
Pfister, H. W., 1442
Phaipun, L., 1393
Phair, J. P., 723, 1217
Piazza, F. M., 1422
Picard, O., 1416
Pichichero, M., 235
Pickering, L., 507
Pickering, L. K., 326
Pickett, M. A., 1173
Pigott, N., 574
Pincus, P., 235
Pinner, R. W., 359
Pizzo, P. A., 121, 668
Plachter, B., 683
Planells, R., 449
Platt, R., 556
Plaut, A. G., 43
Plourde, P. J., 86, 919
Plummer, F. A., 86, 919
Poggensee, L., 1217
Polish, L. B., 518
Pollack, H., 616
Pollack, M., 803, 1429
Pollack, R. J., 827
Pomeroy, C., 677
Pongprot, B., 227
Porat, R., 1204
Porter, K. R., 1403
Portier, H., 428
Portolani, M., 689
Porzsolt, F., 930
Postma, S., 1228
Potts, B. J., 198
Potts, R. C., 182
Poxton, I. R., 1051
Preiksaitis, J. K., 986
Preud'homme, J.-L., 1021
Preziosi, M.-P., 1021
Prince, G. A., 1422
Puccetti, P., 1384
Pugliese, T. J., 205
Pumfery, A. M., 1401
Qiu, J., 43
Que, J. U., 344
Quick, R., 673
Quinlivan, E. B., 80
Quinn, M., 1199
Quinn, T. C., 418
Quiñones, T., 139
Quiroga, J. A., 1200
Racaniello, V. R., 747
Ragazzoni, H., 1433
Rahija, R., 1403
Rangsiyanond, P., 227
Rao, M. R., 1029, 1251
Raoul, H., 93
Raoult, D., 660, 1097
Ras, G. J., 568
Rashbaum, W. K., 699
Rasmussen, G. T., 1375
Raventos-Suarez, C., 598
Raymond, J., 657
Re, M. C., 710
Reddy, M. M., 607
Reed, K. D., 121
Reeves, M., 359
Reeves, W. C., 1210
Reichler, M. R., 1346
Reinacher, M., 783
Remington, J. S., 694
Ren, R., 747
Rennie, R., 1197
Reusser, P., 473
Revello, M. G., 1236
Reves, R. R., 326
Reyes, G. R., 1160
Rice, P. A., 316
Richardson, S., 542
Richman, D. D., 1223
Ries, A. A., 1429
Rietra, P. J. G. M., 209
Riikonen, P., 432
Rijkers, G. T., 1460
Rinaldo, C. R., Jr., 717
Rivero, A., 1201
Rizzoni, G., 154
Roberts, B., 892
Roberts, C. R., 1160
Roberts, N. J., Jr., 244
Roberts, R. L., 486
Roberts, S., 986
Robertson, B. H., 518
Robertson, C. A., 704
Rocha, C. L., 139
Rodewald, A. K., 635
Rodriguez, M., 512
Rogers, M., 892
Roilides, E., 668
Rojas, M., 139
Romani, L., 1384
Romet-Lemonne, J.-L., 93
Ronald, A. R., 86
Rooney, J. F., 500
Roos, M., T. L., 620
Rosas, J., 139
Rosendahl, K., 854
Rosmini, F., 154
Rost, F., 22
Rotbart, H. A., 253
Rothlein, R., 818
Rott, R., 783
Roullet, E., 1416
Roulot, D., 1462
Rousseau, S., 449
Rowe, B., 797
Rozenbaum, W., 611
Rubinstein, A., 699
Ruckdeschel, G., 1442
Ruff, A. J., 194, 418
Ruo, S. L., 753
Rusche, J. R., 198
Russo, R., 448
Saah, A., 1217
Saarinen, U. M., 432
Saavedra, D., 139
Saavedra, M. C., 1203
Sabbagh, R., 1066
Sachdeva, M., 1045
Sack, D. A., 1029, 1251
Sack, R. B., 792
Sáez-Nieto, J., 173
Saito, I., 1425
Saito, T., 1459
Sakurai, M., 941
Salazar, L. M., 139
Salord, J.-M., 1416
Saluja, S., 215
Sampol, J., 660
Sanchez-Guijo, P., 1201
Sanchez-Pescador, L., 623
Sandberg, T., 653
Sanders, C. A., 191
Santos-Gonzalez, J., 1201
Sasada, K., S10
Sato-Matsumura, K. C., 1157
Savatski, L. L., 995
Savić, B., 1177
Sawyer, M. H., 885
Schaad, U. B., 344
Schachter, J., 383, 915
Schaffer, P. A., 494
Scheiblauer, H., 783
Schiff, G. M., 1251
Schmader, K., 1403
Schmall-Bauer, W., 169
Schmidt, H. J., 1422
Schmolke, S., 683
Schneerson, R., 1335
Schoel, B., 186
Schoenfeld, D. A., 717
Scholten-Sampson, A., 1228
Scholz, S., 966
Schoolnik, G. K., 951
Schreiber, J. R., 1346
Schuchat, A., 445
Schumacher-Perdreau, F., 58
Schwartz, D. H., 244
Scotland, S. M., 797
Scott, C. F., 198
Secchiero, P., 689
Seidel, H. D., 296
Seifring, M. L., 53
Selander, B., 1322
Selling, B. H., 769
Semenzato, G., 731
Seminario, L., 1429
Serbousek, D., 1103
Serody, J. S., 1375
Serruys, E., 22
Sethabutr, O., 145
Shaffer, J. M., 1449
Shaffer, N., 892
Shannon, B. T., 525
Shapiro, C. N., 518
Sharief, M. K., 350
Sharma, D. P., 738
Shaw, G. M., 100
Shearer, G. M., 723
Sherman, M. P., 818
Sheu, J.-C., 1167
Sheu, J.-C., 900
Shigemitsu, Y., 1459
Shih, C.-M., 827
Shimoda, K., 1459
Shindo, M., 424
Shiomi, S., 1192
Shiraki, K., S10
Shirao, M., 943
Siber, G. R., 682
Siddique, A. K., 792
Siegel, N., 1362
Sierra, O., 139
Siitonen, A., 1058
Silva, A. T., 331
Silverstein, S., S11
Simmonds, P., 704
Simmons, A., 202
Simmons, R. L., 1379
Simon, T., 958
Singh, S., 215

Sisay, F., 842
Sisler, J. R., 277
Sjöbring, U., 1177
Skerrett, S. J., 1354
Slaney, L. A., 919
Smail, E. H., 866
Small, J. D., 978
Smart, J., 1281
Smith, C. W., 818
Smith, C. R., 1367
Smith, G., 951
Smith, H. R., 797
Smith, J. D., 518
Smith, J. S., 296
Smith, K., 202
Smith, M. S., 80
Smith, M. D., 685
Snitbhan, R., 1465
Soeiro, R., 699
Solary, E., 428
Solomon, L., 685
Sonoda, E., 1295
Sousa, A. de Q., 1124
Spector, S. A., 1412
Spielman, A., 827
Spitalny, K., 1433
Spitzer, J. J., 336
Spratt, B. G., 173
Sprung, C. L., 1367
Spurr, D., 598
Squires, K. E., 686
Stablein, D. M., 244
Stamm, W. E., 1445
Starzl, T. E., 1379
Stein, D. S., 1198
Steinberg, S., S11
Stenqvist, K., 653
Stephens, D. S., 574
Stephens, R. S., 383, 915
Stevens, D. L., 165, 374
Stiehm, E. R., 486
Stiller, R. A., 926
Stojanovic, R., 113
Stoutenbeek, C. P., 209
Straus, S. E., 500, S3
Strickland, G. T., 265
Struelens, M. J., 22
Struewing, J. P., 162, 265
Sturtevant, J., 580
Suchland, R. J., 1445
Sullam, P. M., 65
Sullivan, D. C., 446
Sullivan, G. W., 664
Sullivan, J. L., 1146
Sundqvist, V.-A., 1408
Supawadee, J., 227
Suprasert, S., 227
Suzuki, H., 227
Suzuki, K., 80
Svanborg, C., 653
Swaminathan, B., 574
Swerdlow, D. L., 1429, 1433
Swindell, B. B., 134
Szelc, C. M., 486
Tabrizi, S., 1199
Tabuni, A., 866
Tachedjian, G., 108
Tachibana, H., 1464
Tacket, C. O., 837
Tada, Y., 692
Tajima, K., 943
Takahashi, K., 1425
Takahashi, M., S10
Takala, A. K., 1340
Takasu, T., 1157
Takatsuki, K., 943
Takeuchi, K., 1425
Tamalet, C., 449
Tamura, K., 1295
Taniguchi, K., 227
Tanner, J. E., 53
Tanowitz, H. B., 213, 598
Tashiro, M., 783
Tatarowicz, W. A., 904
Tateno, S., 1464
Täuber, M. G., 546, 1045
Tauxe, R. V., 639, 812, 1429
Taylor, G. W., 568
Taylor, J., 1164
Taylor, M. E., 100
Taylor, J., 1164
Taylor, M. E., 100
Tegzess, A. M., 1228
Teixeira, M. J., 1124
Telford, S. R., III, 827
ten Cate, J. W., 1367
Tennant, B. C., 628
Teppo, A.-M., 432
ter Kuile, F. O., 1393
The, T. H., 683, 1228
Theron, A. J., 568
Thieren, M., 1393
Thiers, V., 1192
Thipphawong, J., 935
Thisyakorn, U., 451
Thomas, M. G., 687
Thomas, P., 892
Thompson, C., 682
Thompson, E. J., 350
Thompson, J., 169
Thompson, K. D., 904
Thornberg, E., 1335
Tilles, J. G., 421
Tingle, A. J., 1258
Tokunaga, S., 1205
Tomoda, T., 908
Tonusin, S., 227
Torosantucci, A., 1103
Torre-Cisneros, J., 1201, 1379
Tosteson, T. D., 556
Toth, L. A., 1266
Trappier, S. G., 753
Trentin, L., 731
Trepo, C., 447
Tripoli, C. A., 717
Trollfors, B., 1335
Trujillo, G., 173
Tsukamoto, H., 692
Tuazon, C. U., 1133
Tucker, R. A., 1210
Tupponce, A. K., 162
Tureen, J. H., 546
Tur-Kaspa, R., 1164
Turner, M. W., 632
Tyndall, M., 919
Tyrrell, D. L. J., 986
Tyssen, D. P., 108
Uchimura, M., 1295
Uhlig, K., 668
Ullberg, M., 1329
Unayama, T., 1425
Underwood, R., 1153
Urasawa, S., 227
Urasawa, T., 227
Urquhart, A. D., 937
Vago, L., 1408
Vaisberg, A., 1170
Valero, M. V., 139
Van, R., 507
van Alphen, L., 1340
van den Berg, A. P., 1228
van der Giessen, M., 683
van der Giessen, M., 1228
van der Gun, B. T. F., 683
van der Horst, C. M., 607
van der Merwe, C. A., 568
van Deventer, S. J. H., 1367
Van De Verg, L. L., 158
van Loon, F. P. L., 1029, 1251
van Son, W. J., 683, 1228
Vasconcelos, A. W., 1124
Vasconcelos, I. de A. B., 1124
Vasquez, E., 1429
Vaudaux, P., 58
Vaughn, S. G., 1073
Vazeux, R., 888
Vázquez, J., 173
Veenstra, J., 209
Velásquez, J. F., 139
Velimirovic, D., 113
Ventura, M. C., 598
Venzon, D., 668
Venzon, D. J., 723
Verdon, M., 1362
Vermund, S. H., 1198
Viens, P., 413
Vignoli, M., 710
Vildé, J.-L., 694
Villanueba, E., 260
Villanueva, J. L., 1201
Villarejo, M., 1311
Viñas, M., 173
Visani, G., 710
Vista, A. L., 202
Vitellozzi, G., 1384
Vlahov, D., 685
von der Möhlen, M. A. M., 1367
Voorn, G. P., 169
Vosefsky, D., 235
Vugia, D. J., 1429
Wachsmuth, I. K., 574
Wagner, R., 866
Wahren, B., 1408
Wainwright, R. B., 1281
Wakasugi, F., 227
Waldner, A., 428
Waldon, J., 942
Waldvogel, F. A., 58, 285
Wali, J. P., 215
Wallace, M. R., 885, 1149
Wallace, R. J., Jr., 405
Wallach, F. R., 938
Walsh, T. J., 121, 668
Walton, R. O., 1346
Wang, H., 436
Wang, J.-T., 1167
Wang, S.-p., 646
Wang, T.-H., 900, 1167
Wang, Z. J., 149
Ward, B. J., 1170
Ward, L., 1217
Ward, M. E., 1173
Ward, R. L., 1251
Ward, T. T., 400
Warner, C. K., 296
Warren, H. B., 635
Wasserman, S. S., 1181
Watanabe, T., 691, 943
Watier, L., 542
Watson, D. A., 38
Watson, S. W., 53
Watt, P. J., 1173
Wattel, E., 212
Webster, H. K., 145, 1393, 1465
Wei, S., 1089
Weiss, L. M., 213
Weiss, P. J., 1149
Weiss, S. H., 896
Weller, T. H., S1
Wellish, M., S4
Wells, J. G., 1429
Wetzler, L. M., 551
Wheeler, A. P., 134
White, C. J., 253
White, L. V. A., 1311
White, N. J., 1393
White, N. J., 1195
White-Scharf, M. E., 198
Whitley, R. J., S9
Whittle, H., 764
Wiker, H. G., 874
Wikler, M. A., 556
Wiktor, S. Z., 418
Wilde, J., 507
Williams, L. L., 525
Willshaw, G. A., 797
Wilson, R., 568
Wittner, M., 213, 598
Wohlenberg, C. R., 500
Wolf, D. G., 1412
Wolf, W., S4
Wolff, A. G., 861
Wolff, S. M., 1204
Wolinsky, J. S., 525
Woodruff, B. A., 518, 1281
Woods, C. R., Jr., 1035

Workowski, K. A., 1445
Wortel, C. H., 1367
Wright, A., 43
Wright, P. W., 134
Wright, P. F., 244
Wright, T. W., 1113
Wu, M., 923
Wu, T., 121
Wu, Y., 885
Xiao, S.-Y., 113
Yabuta, K., 691
Yager, P. A., 296
Yajko, D. M., 191
Yamaguchi, K., 943, 1205
Yamamoto, T., 1295
Yamauchi, Y., 692
Yamazi, Y., 227
Yanagihara, R., 113
Yang, P.-M., 900
Yardley, J. H., 277
Yasuda, N., 941
Yazdanbakhsh, M., 453
Yeaman, M. R., 65
Yerly, S., 269
Yokota, T., 1295
Yolken, R., 507
Yoshimura, K., 943
Young, L. S., 923
Yunus, M., 792, 1029
Zaleznik, D. F., 556
Zambello, R., 731
Zanchetta, N., 1408
Zapata, N., 139
Zauli, G., 710
Zavell, P. J., 38
Zeldis, J. B., 1276
Zeller, V., 428
Zerbe, G. O., 253
Zhang, T., 1258
Zidovudine Epidemiology Study Group, 1223
Zink, M. C., 738
Zipeto, D., 1236
Zucker, J. R., 556, 1458

Subject Index

Acute respiratory disease, prophylaxis with benzathine penicillin G, 365
Acyclovir, for prevention of UV-light reactivation by HSV-2, 500
Adherence
  C. albicans, to tissue of immunodeficient mice, ex vivo, 587
  E. coli, 1295
  S. aureus, methicillin-resistant and -sensitive, 400
  S. epidermidis, to polymers, 861
AIDS
  ampligen for, 717
  CNS infection by
    CMV, detection by PCR, 1209, 1408, 1412, 1416
    JC virus, 80
  epidemiology, survival of men vs. women, 74
  gastric hypoacidity and opportunistic enteric infection, 277
  herpes zoster as predictor of progression, 1153
  maternofetal transmission of HIV-1, 699
  M. avium–M. intracellulare complex infection, IFN-γ for, 686
  murine, effect of cyclosporin A and zidovudine in immune abnormalities, 285
  P. carinii pneumonia in, clindamycin-primaquine for, 694
  pediatric, ADCC, 486
  proctitis in, thalidomide for, 939
  risk of developing CMV infection in, 1223
  stavudine for, 480
  suppression of hematopoesis by HIV-1 in, 710
  zidovudine
    effect on T cell function, 723
    resistance, 1139
Amikacin, postantibiotic effect against MAC, 923
Ampligen, for HIV infection, phase I study, 717
Amphotericin B, resistance in *C. albicans*, 1196, 1197
Animal model
  candidiasis, T cell–depleted mouse, 1384
  CMV, aging and reactivation in latent infection, mouse, 1403
  dilated cardiomyopathy, after rabbit coronavirus infection, 978
  E. faecalis, plasmid transfer, Syrian hamster, 1188
  G-CSF, effect on neutrophils, septic rat, 336
  gram-negative sepsis, role of IFN-γ in experimental infection, mouse, 331
  group B streptococcus infection, neonatal mouse, 635
  HCV, replication during acute infection, chimpanzee, 424
  hepatitis B, chronicity, effect of cyclosporine on, woodchuck, 628
  H. influenzae phagocytosis, capsular inhibition, mouse, 178
  influenza virus infection, role of dsDNA in acute-phase response, rabbit, 1266
  influenza virus–bacteria, pathogenesis of pneumonia, mouse, 783
  inhalation anthrax, antibiotics for, rhesus monkey, 1184
  murine AIDS, cyclosporin A and zidovudine effect on immune abnormalities, 285
  poliovirus, pathogenesis, transgenic mouse, 747
  RSV
    infection, using IgG as aerosol, rat, 1422
    vaccine, dog and chimpanzee, 769
  S. agalactiae pneumonia, preterm rabbit, 818
  S. aureus
    endocarditis, role of tolerance in cloxacillin prophylaxis, rat, 169
    infection, role of TNF in host defense, guinea pig, 58
  S. japonicum, larval migration and attrition, mouse, 1133
  SIV replication, macaque, 738
S. pneumoniae meningitis, cerebral
  metabolism, rabbit, 546
  blood flow, rat, 1442
  surgical wound infection, guinea pig, 393
  T. beigelii infection, persistently granulocytopenic rabbit, 121
  varicella, review, S48
Anthrax, inhalation, penicillin, doxycycline, or ciprofloxacin for, rhesus monkey model, 1184
Antibody-dependent cellular cytotoxicity, in HIV infection, 486
Antibody, heteroconjugate, in vitro inhibition of HIV, 198
Antibody to
  B. pertussis, duration of response, 908
  C. difficile toxin A, 1287
  E. coli LPS core types, 1051
  H. influenzae type b capsular polysaccharide, response in invasive infection, 1335
  HIV-1
    p24 as prognostic factor, 1217
    p25 core protein, as prognostic marker, 611
  hsp 90, in *C. albicans* infection, 1193, 1194
  HTLV-I and -II, in IVDUs, 896
  measles, persistence after revaccination, 205
  M. tuberculosis, after occupational exposure, 182
  N. meningitidis
    class 5c OMP, 1322
    IgA1 protease, 1316
  P. aeruginosa, high-affinity, in cystic fibrosis, 344
  rubella
    response, males vs. females, 1258
    virus antigen, in retinitis pigmentosa, 525
  Shigella species, age-specific prevalence, in Chileans and North Americans, 158
Argentine hemorrhagic fever, levels of TNFα, 1203
Aspergillosis, and liver transplantation, 1379
Aspergillus fumigatus, complement and phagocytosis of conidia, 580
AZT (*See* Zidovudine)

β_2-microglobulin, levels during measles, 1170
Bacillus anthracis, inhalation infection, penicillin, doxycycline, or ciprofloxacin for, rhesus monkey model, 1184
Bacteremia, *S. typhimurium*, association with virulence plasmid, 639
Bacteriuria, asymptomatic, urine and serum concentrations of IL-6, in women, 653
Belgrade virus, hantavirus, cause of severe HFRS, 113
Benzathine penicillin G, prophylaxis for acute respiratory disease and rheumatic fever, 365
Bone marrow transplantation, immunogenicity of *H. influenzae* conjugate vaccine, 1021
Bordetella pertussis, duration of antibody response, 908
Borrelia burgdorferi
  lymphocyte proliferation, T cell response, 938
  spirochete
    dissemination from infection site, 827
    protection from, by ceftriaxone, in vitro, 440
Botulism, clinical differences between toxin types, 1281
Bradyzoite antigens, *T. gondii*, stage-specific MAbs, 213

Campylobacter jejuni, translocation across polarized epithelial cells, 308
Candida albicans
  adherence, to tissue of immunodeficient mice, ex vivo, 587
  amphotericin B–resistant, 1196, 1197
  mannoprotein fraction, effect on PMNL function, 1103
  neutrophil response, to blastoconidia and pseudohyphae, 668
  primary infection, T cell–depleted mouse model, 1384

resistance, conferred by bone marrow, 947
systemic infection, role of antibody to hsp 90, 1193, 1194
Candidiasis, systemic, acquired immunity, immunodeficient mouse model, 1193, 1194
Catheter, central venous, modification of antimicrobial flush, 944
CD4 lymphocyte
initial counts in recent HIV infection, 1149
storage as a factor in counting, 1198
CD4 molecule, role in pathogenesis of HIV-1 infection, 93
CD23 antigen, increased expression during infectious mononucleosis, 691
CD34 progenitor cells, suppression by HIV-1 infection, 710
Cefixime, vs. ceftriaxone, for antimicrobial-resistant gonorrhea, 919
Cell wall polysaccharide, of *S. pneumoniae*, role in assessment of IgG antibodies, 632
Central nervous system infection
CMV, detection by PCR, in AIDS, 1408, 1412, 1416
by JC virus, in AIDS, 80
Cerebral malaria, phagocytic cells in, 937
Cerebrospinal fluid, changes during bacterial meningitis, 350
Chagas' disease
cytokines, role in pathogenesis, 598
seropositivity to *T. cruzi*, in Bolivian blood donors, 1464
Chlamydia pneumoniae, strain TWAR, seroepidemiology, 646
Chlamydia trachomatis
genital infection, associated with serovar and race, 1445
genotyping by nested PCR, Gambian samples, 1173
trachoma
immunoassay of humoral immune response, 915
molecular epidemiology, 383
Chloroquine, and mefloquine, effect on vaccine against *S. typhi*, 1462
Cholera
epidemic
in Peru, 1429
treatment, 2
outbreak, associated with crab, 1433
vaccine
oral, 837
oral, efficacy in *V. cholerae*-endemic area, 1029
Ciprofloxacin
for inhalation anthrax, 1184
and vancomycin, flush for central venous catheter, 944
Citrobacter diversus, interaction with epithelial and endothelial cells, 1035
Clarithromycin, for *M. chelonae chelonae* infection, 405
Clindamycin-primaquine, for *P. carinii* pneumonia, in AIDS, 694
Clostridium difficile
nosocomial infection, colonization, 561
toxin A, antibody, 1287
Cloxacillin, prophylaxis against *S. aureus* endocarditis, role of tolerance in, 169
Cocksackievirus B3, synergism of INF-β and -γ, in infected cultured fibroblasts, 958
Cocultivation, to detect HIV-1, in children <6 months old, comparison of techniques, 616
Complement factor 9, deficiency in neonates, 53
Complement, regulation of activity by vaccinia virus protein, 1245
Condylomata acuminata, factors associated with detection of HPV, 512
Coxiella burnetii, phagolysosomal alkalinization, antibiotic efficacy, 1097
Cryptococcus neoformans, binding and phagocytosis, by human bronchoalveolar macrophages, 866
Cryptosporidium parvum, immunology of infection, review, 465
Cyclosporin A, and zidovudine, role in immune abnormalities in AIDS, 285
Cystic fibrosis, induction of high-affinity antibodies to *P. aeruginosa*, 344
Cytokine
induction of multinucleated giant cells, 664
release from microglial cells, effects of pentoxifylline and dexamethasone, 847
serum levels during fever and neutropenia, in children, 432
Cytomegalovirus
antigenemia assay, 683
detection in CNS, in AIDS, 1209, 1408, 1412, 1416
ganciclovir-resistant, clinical isolate, 904
glycoprotein H, molecular epidemiology, 604
infection
of leukocyte populations, in viremic patients, 1236
in marrow transplant recipients, foscarnet for prevention, 473
natural history of disease, in HIV infection, 1223
recovery associated with PBL activation, 1228
murine, aging and reactivation in latent infection, 1403
and reactivation of *T. gondii* pneumonia, 677
replication, in PMNL from viremic patients, 1236
retinitis, in AIDS, effect of foscarnet on p24 antigen levels, 607

d4T (*See* Stavudine)
Dexamethasone, effect on cytokine release from microglia, 847
Diarrhea
acute and persistent, in Bangladeshi children, 792
in AIDS, role of stomach acid, 277
rotavirus
prevalence of serotypes, in Thai children, 227
protection after natural infection, 1251
Dideoxycytidine, combination therapy for zidovudine-resistant HIV, 1143
Dideoxynucleosides, effect on survival in AIDS, 74
Diethylcarbamazine, in filariasis, adverse reactions, mediated by IL-6, 453
Dilated cardiomyopathy, after rabbit coronavirus infection, animal model, 978
DNA
double-stranded, role in acute-phase response, in influenza, 1266
polymerase, mutation, in human CMV, 904
probes, to detect *M. intracellulare* and "X" mycobacteria among MAC clinical isolates, 191
RFLP analysis, of ribosomal RNA genes of *S. agalactiae*, 574
Doxycycline, for inhalation anthrax, 1184

Echinococcosis, splenic, clinical and serologic evaluation, 695
ELISA-based sequence-defined assay, to detect *C. trachomatis* MOMP, 915
Encephalitis, after treatment of uncomplicated *P. falciparum* infection, 1195, 1196
Endocarditis, *S. aureus*, cloxacillin prophylaxis for, rat model, 169
Endotoxemia, plasma GM-CSF, 1204
Enterococcus faecalis, plasmid transfer, Syrian hamster model, 1188
Epidemiology
AIDS
risk of developing CMV infection in, 1223
survival of men vs. women, 74
B. pertussis, duration of antibody response, 908
botulism, clinical differences between toxin types, 1281
C. difficile, nosocomial infection, colonization, 561
Chagas' disease, seropositivity in Bolivian blood donors, 1464
cholera, epidemic, treatment, 2
C. pneumoniae strain TWAR, serologic study of families, 646
C. trachomatis genital infection, risk factors, 1445
diarrhea, in Bangladeshi children, 792

E. coli, trimethoprim-resistant, in households of children in day care, 326
filovirus, role of geographic origin of primate host and virus strain, 753
G. lamblia, outbreak, restaurant-associated, 673
group A streptococci
β-hemolytic, infection, in recruits receiving penicillin prophylaxis, 1006
genetic diversity, 1014
infection, pathogenesis, 31
serotypes associated with specific clinical infections, 374
hantavirus, Belgrade virus, cause of severe HFRS, 113
HCV transmission
interspousal, 900
from mothers with chronic infection, 1192
vertical, PCR use, 1425
hepatitis A multistate outbreak, associated with frozen strawberries, 518
herpes zoster, incidence in HIV-infected homosexual men, 1153
HIV-1 transmission
heterosexual, in Africa, 86
maternofetal, 699
vertical, and V3 antibodies, 704
HPV, colposcopic changes and DNA variability, 951
H. pylori, risk factors for infection, in southern China, 149
HTLV-I and -II
heterogeneity of immune responsiveness, 1160
infection, in IVDUs, 896
HTLV-II
endemicity, among remote South American Indians, 100
transmission, mother-to-child, 892
intestinal parasites, persistence in nonendemic regions, 413
legionellosis, hospital outbreak, 22
leishmaniasis, visceral, in northeast Brazil, 1124
M. chelonae chelonae infection, risk factors, 405
meningococcal disease
association with influenza-like syndrome, 542
in Kenya, 359
onchocerciasis, treatment, 15
rabies virus, sequencing of nucleoproteins, 296
rotavirus
detection, by PCR, in day care center, 507
diarrhea
prevalence of serotypes, in Thai infants, 227
protection after natural infection, 1251
Shigella species, prevalence of antibody to, in Chile and North America, 158
S. pneumoniae, multiply resistant, spread in day care center, 1346
T. cruzi, seropositivity in Bolivian blood donors, 1464
T. pallidum infection and pregnancy outcome, in The Gambia, 842
T. vaginalis, risks and diagnosis in men, 1362
toxic shock syndrome, reporting, 445
V. cholerae infection
epidemic, Peruvian, 1429
outbreak, 1433
Vero cytotoxin–producing *E. coli*, and hemolytic-uremic syndrome, in Italy, 154
Y. enterocolitica, sporadic infections, in Norway, 812
Epstein-Barr virus
antibody, and subclinical *P. carinii* pneumonitis, 926
in organ transplant recipients, risk of lymphoproliferative disorder, 986
Errata
Cannon et al., 1991;164:860–3, 698
De Maria et al., 1992;165:917–9, 950
Kern et al., 1992;166:930–4, 1467
Erythromycin, prophylaxis against *S. pyogenes*, in penicillin allergy, 162
Escherichia coli
diarrheagenic, and adherence, 1295
growth in human urine, osmotic tolerance, 1311
LPS
core types, 1051
heterogeneity, 803
neutralization by polymyxin B, 682
serogroups producing Vero cytotoxin, 797
trimethoprim-resistant, in households of children in day care, 326
vaccination, cross-reactive antigonococcal antibody, 316
virulence-associated characteristics, in normal feces, 1058
VTEC, cause of hemolytic-uremic syndrome, 154
Ethanol treatment, and second-messenger generation in PMNL, 854
Exanthem subitum, isolation and characterization of HHV-6, 689
Exotoxin, *S. pyogenes*, effect on PMNL adherence, 165

Fever, as indicator of severity in *S. sonnei* infection, 1181
Fibroblasts, role in Lyme disease, 440
Filariasis
lymphatic, IL-6 and reactions to diethylcarbamazine, 453
W. bancrofti protein, antigenicity in human disease, 1453
Filovirus, pathogenesis, role of geographic origin of primate host and virus strain, 753
Flow cytometry analysis of
bacterial platelet binding, 65
E. coli J5 LPS heterogeneity, 803
Foreign body infection, due to *S. aureus*, role of TNF in host defense, 58
Foscarnet, for
AIDS, effect on HIV p24 antigen levels in AIDS patients with CMV retinitis, 607
CMV infection, prevention, 473
HSV, infection during therapy, 447

Ganciclovir, resistance of CMV clinical isolate, 904
Ganglia, latent infection by VZV, S24
Gastroenteritis, *Y. enterocolitica*, sporadic infections in Norway, 812
Gb3, receptor glycolipid for Shiga toxin, in human milk, 832
Giardia lamblia
immunology of infection, review, 465
outbreak, restaurant-associated, 673
Glycoprotein B, of HSV-1 and -2, functional activity of MAbs to, 623
Gonorrhea, antimicrobial-resistant infection, cefixime vs. ceftriaxone for, 919
Gram-negative sepsis, effectiveness of monoclonal anti-endotoxin antibody, 1367
Granulocyte colony-stimulating factor, effect on neutrophils, septic rat model, 336
Granulocyte-macrophage colony-stimulating factor, synthesis, during endotoxemia, 1204
Group A streptococci
genetic diversity, 1014
infection
β-hemolytic, in recruits receiving penicillin prophylaxis, 1006
pathogenesis, 31
serotypes associated with specific clinical infections, 374
Group B streptococcal infection
molecular epidemiology, 574
neonatal mouse model, 635
Group C *N. meningitidis*, killing by neutrophils, 1079

Haemophilus influenzae
growth in human milk, 43
type b
antibody response, to capsular polysaccharide, in invasive infection, 1335

phagocytosis, capsular inhibition of, mouse model, 178
subtypes and vaccination, 1340
vaccine, conjugate, immunogenicity in bone marrow recipients, 1021
Hantavirus, Belgrade virus, cause of severe HFRS, 113
Helicobacter pylori
infection, risk factors in southern China, 149
vacuolating toxin, potentiation by weak bases, 1073
Hemagglutinin neuraminidase genes, of parainfluenza virus type 1, variation and evolution, 995
Hemolytic-uremic syndrome, due to Vero cytotoxin–producing *E. coli*, 154
Hemorrhagic fever with renal syndrome, due to Belgrade virus, 113
Hepatitis A, multistate outbreak, associated with frozen strawberries, 518
Hepatitis B virus
infection
acute and fulminant, serum TNF in, 448
and HIV-1 and HTLV-I infection, in Haitian women, 418
replication, effect of IFNs, 966
vaccine
efficacy, in children from
S. mansoni–endemic village, 265
The Gambia, 764
recombinant DNA, effect in teenagers, 942
viremia, effect of malaria on, 1465
Hepatitis C virus
detection
in PBMC
of infected patients, 1276
of replicative form, 1167
by PCR
in indeterminate recombinant immunoblot assay, 449
or RIBA, 450
infection
chronic, retreatment with IFN-α, 1200
replication during, chimpanzee model, 424
transmission
interspousal, 900
from mothers with chronic infection, 1192
vertical, use of PCR, 1425
Hepatitis delta virus, IFN-α for, 1164
Hepatoblastoma cells, transfection with HBV DNA, 966
Herpes simplex virus
effect on latent HIV, in ACH-2 cells, 494
infection
corneal, IFN-α and -γ for, 1401
during foscarnet therapy, 447
latent, S13
trifluorothymidine and IFN-α for, clinical and in vitro studies, 108
Herpes simplex virus type 2 infection
and HIV-1 and HTLV-I infection, in Haitian women, 418
UV-light reactivation, prevention by acyclovir, 500
Herpes simplex virus types 1 and 2, glycoprotein B, functional activity of MAbs to, 623
Herpes zoster
antibody, levels in systemic lupus erythematosis, 692
incidence, in HIV-infected homosexual men, 1153
Hookworm, persistence in refugee populations, 413
Human herpesvirus 6
characterization of exanthem subitum isolates, 689
detection by in situ hybridization, in Rosai-Dorfman disease–affected tissues, 291
replication in
epithelial cells, in vitro, 202
HTLV-I–transformed cells, 446
Human herpesvirus 7, strain JI, independent confirmation of HHV-7, 690
Human immunodeficiency virus type 1
activation by HSV, 494
in AIDS patients with CMV retinitis, effect of foscarnet on p24 antigen levels, 607
association with p24 antibody, CD4 lymphocyte number, and AIDS-free time, 1217
CD4 molecule, role in pathogenesis, 93
detection
in children <6 months old, comparison of techniques, 616
by PCR and serologic assay, concordance, 620
diagnosis by whole blood culture, 1146
gp160 recombinant vaccinia virus vaccine, safety and efficacy, 244
infection
ADCC, 486
ampligen for, 717
association with cervical HPV, in Zaire, 1210
CD4 lymphocyte counts, 1149
and CMV, in zidovudine-treated patients, 1223
herpes zoster as predictor of progression, 1153
and HSV-2, in Haitian women, 418
IL-6 production, 731
among IVDUs, knowledge of therapeutics, 685
proctitis in, thalidomide for, 939
and syphilis, in Haitian women, 418
tuberculin skin test reactivity in, 194
zidovudine
effect on T helper cell function, 723
resistance, 1139
predictive value of anti-p24 antibodies, 611
quantification of provirus and circulating virus, 269
storage as a factor in counting CD4 lymphocytes, 1198
suppression of hematopoesis, in AIDS, 710
transmission
heterosexual, in Africa, 86
maternofetal, 699
vertical, and V3 antibodies, 704
in tuberculosis, effect on cell-mediated immunity, 1201
virologic and seroimmunologic parameters, 269
in vitro inhibition by heteroconjugate antibody, 198
zidovudine resistance, combination therapy, 1143
Human immunodeficiency virus type 2, detection in brain tissue, 888
Human papillomavirus
cervical, from HIV-1–infected women, 1210
colposcopic changes and DNA variability, 951
condylomata acuminata, detection of viral proteins, 512
replication, influence of menstrual cycle, 1199
Human T lymphotropic virus
type I
infection, and HSV-2, in Haitian women, 418
uveitis, seroepidemiologic, clinical, and virologic studies, 943
type II
endemicity, among remote South American Indians, 100
transmission, mother-to-child, 892
types I and II
DNA, absence in HTLV I/II-negative IVDUs, 212
immunodominant epitopes, 1160
screening, diagnosis, and confirmation, 896

IDSA membership information (December 1992 issue)
IDSA annual meeting
preliminary program, 455
presentation
onchocerciasis, treatment, 15
cholera, epidemic, 2

IgA, secretory, in human milk, 43
IgA1 protease, *N. meningitidis*, antibody to, 1316
IgG antibody to *S. pneumoniae*, 632
Immunofluorescence, indirect, to detect *R. conorii* in endothelial cells, 660
Immunoglobulin, intravenous, *S. pneumoniae* antibody in commercial preparations, 38
Immunohistology, to detect HIV-2, 888
In situ hybridization, to detect HIV-2, 888
Infectious mononucleosis, increased expression of CD23 during, 691
Influenza virus
  infection, role of dsDNA in acute-phase response, rabbit model, 1266
  pneumonia, role of bacteria in pathogenesis, mouse model, 783
Interferon, inhibition of HBV replication, 966
Interferon-α
  and -γ, for HSV corneal infection, 1401
  for HCV infection, retreatment, 1200
  for HDV infection, 1164
  subtypes, absence of intrathecal synthesis in bacterial meningitis, 657
  and trifluorothymidine, for HSV infection, clinical and in vitro studies, 108
  for zidovudine-resistant HIV, combination therapy for, 1143
Interferon-β, and -γ, synergism in coxsackievirus B3–infected cultured fibroblasts, 958
Interferon-γ
  and -β, synergism in coxsackievirus B3–infected cultured fibroblasts, 958
  for bacillemia due to *M. avium–M. intracellulare* complex, in AIDS, 686
  effect on alveolar macrophages in killing *L. pneumophila*, 1354
  in experimental gram-negative infection, 331
Interleukin-1
  role in bacterial meningitis, 350
  serum levels, during fever and neutropenia, in children, 432
Interleukin-6
  intrathecal concentrations, during meningitis, 428
  levels
    and adverse reactions to diethylcarbamazine, in filariasis, 453
    during fever and neutropenia, in children, 432
  production by alveolar macrophages, from HIV-1–infected subjects, 731
Interleukin-8, activation of calcium influx, in neutrophils, 1089
Intestinal parasites, persistence in nonendemic regions, 413
Intravenous gamma globulin, for tetanus, 642

JC virus, subclinical infection, in AIDS, 80

Kala-azar, resistant to antimony and pentamidine, ketoconazole for, 215
Ketoconazole, for antimony- and pentamidine-resistant kala-azar, 215

Lactoferrin, and LPS interaction, 1375
Lagos bat virus, isolate from Ethiopia, characterization, 972
Legionella pneumophila
  DNA, restriction endonuclease analysis, 22
  epidemiology and control, 22
  killing by alveolar macrophages, 1354
Leishmaniasis, visceral, in northeast Brazil, 1124
Lentivirus, effect of viral load in lymphoid interstitial pneumonia, 531
Lipopolysaccharide
  E. coli
    core types, 1051
    J5, heterogeneity, 803
  and lactoferrin interaction, 1375
  in meningococcal disease, levels in plasma and CSF, 650
Liver transplantation, development of aspergillosis in, 1379
Lyme disease
  lymphocyte proliferation, T cell response, 938
  spirochete
    dissemination, 827
    protection by fibroblasts from ceftriaxone, in vitro, 440
Lymphocyte
  CD4, storage as a factor in counting, 1198
  subsets, correlation with CMV antigenemia and clinical symptoms, 1228
Lymphoid interstitial pneumonia, due to ovine lentivirus, effect of viral load, 531

Macrophage
  alveolar, effect of IFN- on killing of *L. pneumophila*, 1354
  bronchoalveolar, binding of *C. neoformans*, 866
  function, compared with multinucleated giant cell function, 664
Malaria
  cerebral, phagocytic cells in, 937
  multiresistant, high-dose mefloquine for, 1393
  P. falciparum
    detection by PCR, field study, 145
    effect on HBV viremia, 1465
    increase of TNF and TNF receptors, 930
    smear-negative, mefloquine-resistant, 1458
  safety and immunogenicity of synthetic vaccine, 139
Malnutrition, as an immunodeficiency, 1458
Marrow transplant recipients, foscarnet for prevention of CMV infection, 473
Measles
  antibody, persistence after revaccination, 205
  immune activation in, β_2-microglobulin levels, 1170
  viremia
    degree and length, in adults, 421
    prolonged, in children, 941
Mediterranean spotted fever, diagnosis by indirect immunofluorescence of *R. conorii*, in endothelial cells, 660
Mefloquine
  and chloroquine, effect on vaccine against *S. typhi*, 1462
  high-dose, for multiresistant malaria, 1393
  resistance, in *P. falciparum* malaria, 1458
Meningitis
  bacterial
    blood-brain barrier damage, 350
    IFN- α subtypes, absence of, 657
    and nonbacterial, intrathecal IL-6, 428
  C. diversus, invasion and adhesion, 1035
  N. meningitidis, in Kenya, 359
  S. pneumoniae
    cerebral
      metabolism, 546
      blood flow and edema, rat model, 1442
    or *E. coli*, neurotoxic factors, 1045
Meningococcal disease
  association with influenza-like syndrome, 542
  epidemic, in Kenya, 359
  LPS levels, in plasma and CSF, 650
Methicillin, resistance, in *S. aureus*, after surgery, 1459
Mokola virus, isolate from Ethiopia, characterization, 972
Monoclonal antibodies
  for characterization of street rabies viruses, 972
  T. gondii bradyzoite stage-specific, 213
  to
    E. coli LPS core types, 1051
    endotoxin, in gram-negative sepsis, 1367
    N. meningitidis class 5c OMP, 1322
Mononuclear cells, cytotoxicity in HIV infection, 486

Multinucleated giant cells, candidacidal activity and oxidative capacity, 664
Mycobacterium avium, postantibiotic effect of amikacin and rifapentine, 923
Mycobacterium avium–M. intracellulare complex, bacillemia, in AIDS, IFN-γ for, 686
Mycobacterium chelonae chelonae, skin, soft tissue, and bone infections, 405
Mycobacterium intracellulare, detection by DNA probe, among MAC clinical isolates, 191
Mycobacterium tuberculosis
38-kDa protein, review, 874
antibody, after occupational exposure, 182
detection in sputum, by PCR, 1177
infection
effect on cell-mediated immunity, in HIV infection, 1201
PPD size, in HIV-1 infection, 194
secreted antigens, characterization, 186
Myocarditis, due to enterovirus, IFNs for, in vitro, 958

Neisseria gonorrhoeae
antimicrobial-resistant infection, cefixime vs. ceftriaxone for, 919
killing, by cross-reactive antibody induced by *E. coli J5* vaccination, 316
plasminogen receptors, 1329
vaccine against porin, evaluation, 551
Neisseria meningitidis
class 5c OMP, MAbs to, 1322
epidemic disease, in Kenya, 359
group C, killing by neutrophils, 1079
IgA1 protease, antibody to, 1316
infection, association with influenza-like syndrome, 542
lipooligosaccharide, neutralization by polymyxin B, 682
penicillin-resistant, genetic diversity, 173
plasminogen receptors, 1329
Neonate, complement factor 9 deficiency, 53
Neutrophil
oxidative burst, in response to *C. albicans*, 668
effect of G-CSF on, in septic rats, 336
Non-A, non-B hepatitis, comparison of detection by RIBA or PCR, 450
Nonsteroidal antiinflammatory drugs, effect on *S. epidermidis* adherence to polymers, 861
Nosocomial infection, *C. difficile*, colonization, 561

Onchocerciasis, treatment, 15
Opportunistic infection, enteric, in AIDS, association of gastric hypoacidity, 277

p24 antibody, as predictor of progression to AIDS, 1217
p25 core protein, as predictor of progression to AIDS, 611
Parainfluenza virus type 1, genetic variation and evolution, 995
Peliosis hepatis, *R. henselae*, rRNA sequence in liver, 1462
Penicillin
for inhalation anthrax, 1184
prophylaxis for acute respiratory disease, 365
Pentoxifylline, effect on cytokine release from microglia, 847
Pertussis, vaccine, multicomponent, 1436
Phagocytosis, of *H. influenzae*, capsular inhibition, 178
Pharyngitis, group A streptococci, prophylaxis with penicillin, 1006
Phenazine pigments, of *P. aeruginosa*, in vitro effects, 568
Plasma antigen capture, to detect HIV-1 in children <6 months old, comparison of techniques, 616
Plasmin, generation by streptokinase-producing streptococci, 436
Plasminogen, receptors on *N. meningitidis* and *N. gonorrhoeae*, 1329
Plasmodium falciparum
detection by PCR, field study, 145
malaria
effect on HBV viremia, 1465
increase of TNF and TNF receptors, 930
multiresistant, high-dose mefloquine for, 1393
smear-negative
cerebral, 1195, 1196
mefloquine-resistant, 1458
Platelets, binding by bacterial pathogens, 65
Pneumocystis carinii
cloning of surface protein, 1113
expression of recombinant antigen, 1113
pneumonia, clindamycin-primaquine for, in AIDS, 694
Pneumonia
influenza virus–bacteria synergism, 783
P. carinii
clindamycin-primaquine for, in AIDS, 694
in nonimmunocompromised adult, 926
S. agalactiae, effect of anti-CD18 MAb, 818
Poliovirus
neural spread from muscle to CNS, transgenic mouse model, 747
vaccination schedule and reversion to virulence, 935
Polymerase chain reaction, to detect
CMV, in CNS, in AIDS, 1209, 1408, 1412, 1416
C. trachomatis DNA, 1173
HCV
compared with RIBA, 450
RNA, 449, 1276
vertical transmission, 1425
HIV-1
in children <6 months old, comparison of techniques, 616
concordance with serologic assay, 620
HIV-2, 888
HTLV-I and -II, 896
M. tuberculosis DNA in sputum, 1177
P. falciparum, field study, 145
rotavirus, on fomites, 507
VZV
DNA, 885, S24, S30
in human geniculate ganglia, 1157
Polymorphonuclear leukocyte
activity against *C. albicans*, 1103
calcium influx activation by IL-8, 1089
cytotoxicity in HIV infection, 486
effects of ethanol on diacylglycerol generation, 854
phagocytosis of *A. fumigatus* conidia, role of complement, 581
Posttransplant lymphoproliferative disorder, role of EBV in pathogenesis, 986
Pregnancy, and treponemal infection, outcome, 842
Probenecid, effect on zidovudine pharmacokinetics, 687
Proctitis, in AIDS, thalidomide for, 939
Progressive multifocal leukoencephalopathy, due to JC virus, in AIDS, 80
Prostatitis, chronic, due to *T. vaginalis*, 1205
Protease inhibitor, combination therapy for zidovudine-resistant HIV, 1143
Pseudomembranous colitis, *C. difficile*, nosocomial infection, 561
Pseudomonas aeruginosa
induction of high-affinity antibodies, in cystic fibrosis, 344
phenazine pigments, in vitro effects, 568
Pulmonary toxicity, due to amphotericin B, effect of ibuprofen, sheep model, 134

Rabies-related viruses, isolates from Ethiopia, characterization, 972
Rabies virus
from Ethiopia, characterization with MAbs, 972
sequencing of nucleoproteins, 296

Ramsay Hunt syndrome, detection of VZV in geniculate ganglia, 1157
Reactivation, of HSV-2 by UV light, prevention by acyclovir, 500
Respiratory syncytial virus
  infection, IgG aerosol for, rat model, 1422
  vaccine, adenovirus-vectored, 769
Restriction endonuclease analysis, of *S. agalactiae* chromosomal DNA, 574
Retinitis pigmentosa, serum antibodies to rubella virus proteins, 525
Rheumatic fever, prophylaxis in recruits, 1006
Rhinovirus, infection, combined treatment for, 776
RIBA, to detect HCV, compared with PCR, 449
Rickettsia conorii, detection by indirect immunofluorescence, in endothelial cells, 660
Rifapentine, postantibiotic effect against MAC, 923
RNA, double-stranded, mismatched (ampligen), for HIV infection, 717
Rochalimaea henselae, rRNA sequence in liver, in bacillary peliosis hepatis, 1462
Rosai-Dorfman disease, detection of HHV-6, by in situ hybridization, 291
Rotavirus
  detection by PCR, on fomites, 507
  diarrhea, protection after natural infection, 1251
  human, antigenic and genetic analysis, relationship with animal rotavirus, 227
  rhesus, VP7 serotype 3 or 1 vaccine, field trial, 235
Rubella virus antibody
  response in males vs. females, 1258
  serum, in retinitis pigmentosa, 525

Salmonella typhimurium, bacteremia, association with virulence plasmid, 639
Salmonella typhi oral vaccine
  immunogenicity, impairment of, 210
  inhibition of, by mefloquine and chloroquine, 1462
  TY21a liquid formulation, safety and immunogenicity, in children, 451
Schistosoma japonicum, larval migration and attrition, mouse model, 1133
Schistosoma mansoni, infection, effect on hepatitis B immunization, 265
Second-generation immunoblot assay, vs. PCR, to detect HCV, 449
Sepsis, gram-negative
  effectiveness of monoclonal anti-endotoxin antibody, 1367
  role of IFN-γ in experimental infection, mouse model, 331
Shiga toxin
  amphotericin B–induced lung injury, in sheep, effect of cyclooxygenase inhibition on, 134
  receptor glycolipid, in human milk, 832
Shigella sonnei, infection, fever as indicator of severity, 1181
Shigella species, antibodies to LPS and Ipa of, 158
Shigellosis, relationship between oral temperature and severity, 1181
Simian immunodeficiency virus, viral replication, 738
Staphylococcus aureus
  binding to platelets, characterization by flow cytometry, 65
  endocarditis, role of tolerance in cloxacillin prophylaxis, rat model, 169
  foreign body infection, role of TNF in host defense, 58
  infection after surgery, methicillin resistance, 1459
  methicillin-resistant and -sensitive, adherence, 400
  surgical wound infection, guinea pig model, 393
  toxic shock syndrome toxins, 911
  vancomycin and teicoplanin resistance, 1066
Stavudine, pharmacokinetics in AIDS patients, 480
Streptococci, streptokinase-producing, acquisition of plasmin activity, 436
Streptocci, group A
  genetic diversity, 1014
  infection
    β-hemolytic, in recruits receiving penicillin prophylaxis, 1006
    pathogenesis, 31
Streptococcus agalactiae
  molecular epidemiology, 574
  pneumonia, macrophage- and neutrophil-mediated killing, 818
Streptococcus pneumoniae
  antibody to capsular polysaccharide, in commercial IVIG preparations, 38
  cell wall polysaccharide, role in assessment of IgG antibodies, 632
  meningitis, cerebral
    metabolism, rabbit model, 546
    blood flow and edema, rat model, 1442
  multiply resistant, spread in day care center, 1346
  vaccine, response in splenectomized patient, 1460
Streptococcus pyogenes
  acute rheumatic fever, prophylaxis with benzathine penicillin G, 365
  exotoxins, effect on PMNL adherence, 165
  prophylaxis with erythromycin, in penicillin allergy, 162
Strongyloides species, persistence in refugee populations, 413
Superoxide production, in PMNL, effects of ethanol on, 854
Surgical wound infection
  antibiotic prophylaxis after herniorrhapy or breast surgery, 556
  low-inoculum model, 393
Syphilis
  and HIV-1 and HTLV-I infection, in Haitian women, 418
  and pregnancy outcome, in The Gambia, 842
  susceptibility of *T. pallidum* to phagocytosis, 1449
Systemic lupus erythematosis, antibody levels to VZV, 692

T lymphocyte
  immunity to VZV, S35
  reconstitution of function, after zidovudine therapy, 723
Teicoplanin, resistance, in *S. aureus*, 1066
Tetanus, IVIG for, 642
Thalidomide, for AIDS-associated proctitis, 939
Toxic shock syndrome
  enterotoxins, 911
  reporting, 445
Toxin A, *C. difficile*, antibody, 1287
Toxins, botulism, clinical differences between types, 1281
Toxoplasma gondii
  bradyzoite stage-specific MAbs, 213
  pneumonia, CMV-induced reactivation, mouse model, 677
Trachoma
  ELISA-based sequence-defined assay, to detect *C. trachomatis*, 915
  genotyping by PCR, 1173
  molecular epidemiology of *C. trachomatis*, gene variant regions, 383
Treponema pallidum infection
  and pregnancy outcome, 842
  susceptibility to phagocytosis, 1449
Tribute, to Joel Meyers, 1
Trichomonas vaginalis
  in chronic prostatitis, determined by culture, 1205
  infection, in men, risks and diagnosis, 1362
Trichosporon beigelii, infection, granulocytopenic rabbit model, 121
Trifluorothymidine, and IFN-α for HSV infection, clinical and in vitro studies, 108
Trimethoprim, *E. coli* resistance, in households of children in day care, 326
Trypanosoma cruzi
  infection, cytokine gene expression, 598
  seropositivity, in Bolivian blood donors, 1464
Tuberculosis
  diagnosis by PCR, 1177
  effect on cell-mediated immunity, in HIV infection, 1201

PPD skin test reactivity in HIV-1 infection, 194
specific immune responses, review, 874
specificity of antibodies and tuberculin response, after occupational exposure, 182
Tumor necrosis factor
in acute and fulminant HBV infection, 448
role in
bacterial meningitis, 350
host defense against staphylococci, guinea pig model, 58
and TNF receptors, correlate with parasitemia and disease severity, in malaria, 930
Tumor necrosis factor-α
in Argentine hemorrhagic fever, 1203
serum levels, during fever and neutropenia, in children, 432
Two-dimensional PAGE, for study of T cell antigens of *M. tuberculosis*, 186

Urinary tract infection
E. coli, growth, 1311
IL-6 concentrations, in urine and serum, 653
Uveitis, HTLV-I, seroepidemiologic, clinical, and virologic studies, 943

Vaccine
HIV-1 gp160 recombinant vaccinia virus vaccine, safety and efficacy, 244
S. typhi Ty21a
preexisting antibodies, impaired immunogenicity, 210
liquid formulation, safety and immunogenicity, in children, 451
Vaccine against
cholera, efficacy in an *V. cholerae*–endemic area, 1029
gonococcal porin, evaluation, 551
HBV, long-term protection, in Gambian children, 764
hepatitis B
in children from *S. mansoni*–endemic village, 265
in teenagers, 942
H. influenzae type b conjugate
in bone marrow recipients, 1021
effectiveness against subtypes, 1340
malaria, safety and immunogenicity, 139
measles, persistence of antibody, 205
pertussis, multicomponent, 1436
poliovirus, combined schedule, 935
rhesus rotavirus VP7 serotype 3 or 1, field trial, 235
RSV, adenovirus-vectored, immuogenicity, 769
S. pneumoniae, response in splenectomized patient, 1460
S. typhi, inhibition by mefloquine and chloroquine, 1462
varicella, S58, S63
V. cholerae, oral, 837
VZV, 253, 260
Vaccinia virus, regulation of complement activity, 1245
Vacuolating toxin, *H. pylori*, potentiation by weak bases, 1073
Vamcomycin
and ciprofloxacin, flush for central venous catheter, 944
resistance, in *S. aureus*, 1066
Varicella
animal models, S48
immunization of for elderly and patients with collagen vascular diseases, S58
neonatal infection, S42
in pregnancy, effect on fetus, S42
vaccine, review, S63
Varicella-zoster virus
antibody levels, in systemic lupus erythematosis, 692
cell-mediated immunity to, S35
DNA, detection in oropharynx and blood, 885
historical perspective and overview, S1
in human geniculate ganglia, detection by PCR, 1157
infection
gene expression during latency, S24
in HIV-infected homosexual men, 1153
latent, S13
therapy, review, S51
intracellular synthesis, S7
neurologic and visceral diseases, without rash, S30
reactivation without rash, S30
vaccine, immune response of
elderly, 253
young adults, 260
Vero cytotoxin, *E. coli*
hemolytic-uremic syndrome, 154
properties, 797
Vibrio cholerae
challenge in volunteers, 837
infection
efficacy of oral vaccine, 1029
epidemic, Peruvian, 1429
outbreak, associated with crab, 1433
Vibrio vulnificus, indole-negative, transmission by eels, 209
Virulence
E. coli
characteristics, in normal feces, 1058
Vero cytotoxin–producing 797
Salmonella, plasmid, role in bacteremia, 639

Whole blood culture, to diagnose HIV-1 infection, 1146
Woodchuck hepatitis virus, immunosuppression with cyclosporine during incubation, 628
Wound infection
antibiotic prophylaxis after herniorrhapy or breast surgery, 556
surgical, low-inoculum model, 393
Wucheria bancrofti, protein, antigenicity in human disease, 1453

"X" mycobacterium, detection by DNA probe, among MAC clinical isolates, 191

Yersinia enterocolitica, sporadic infections, 812

Zidovudine
and cyclosporin A, role in immune abnormalities in AIDS, 285
effect on
survival in AIDS, 74
T helper cell function, in HIV infection, 723
HIV resistance
combination therapy, 1143
development of, 1139
pharmacokinetics, effect of probenecid, 687
Zoster, prevention by varicella vaccination, S58
Zoster sine herpete, review, S30